Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // November 2nd, 2010 // 7:12 am
Good morning, everyone. Nice to see you again. A nippy day here on the Pharmalot corporate campus, where we are brewing a cup of stimulation to keep warm, not just alert. As always, meetings and deadalines loom, so the time has come to dig into the news of the day. Here are a few items of interest. And please let us know of anything that warrants attention. See you soon…
Pfizer Profit Beats Esimates On Lower Costs (Bloomberg News)
Avanir Stock Soars On Approval For Pseudobulbar Effect Drug (Reuters)
Amgen CEO: FDA Safety Focus Is ‘Extreme’ (Dow Jones)
McKesson Pays $2B To Buy US Oncology (The Wall Street Journal)
Lilly To Open Diabetes Center In China (PharmaTimes)
Novartis Downplayed Bone Drug Risks, Lawyers Says (Bloomberg News)
Nektar To Supply Amgen With Polymer (Reuters)
Coffee pix thx to chichcacha flickr creative commons
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Amgen, Avanir, China, Diabetes, Drug Safety, Eli Lilly, FDA, McKesson, Nektar Therapeutics, Novartis, Pfizer, Polymer, Pseudobulbar, US Oncology, Zometa